Abstract LB_C09: QTX3034, a potent and selective multi-KRAS inhibitor, synergizes with EGFR inhibitors and enhances anti-tumor activity

阿法替尼 克拉斯 西妥昔单抗 埃罗替尼 表皮生长因子受体抑制剂 癌症研究 体内 药理学 癌症 表皮生长因子受体 生物 医学 结直肠癌 内科学 生物技术
作者
Yang J. Zhang,Jillian M. Silva,Yang W. Zhang,Elizabeth Donohue Vo,John M. Micozzi,Douglas Krauth,Arghyotri Sinha,Ben Reid,Brooke McDonough,Gregory M. Lee,Christopher C. Pan,Audrey Hospital,Juan I. Luengo,Cameron Pitt,Hong Lin
出处
期刊:Molecular Cancer Therapeutics [American Association for Cancer Research]
卷期号:22 (12_Supplement): LB_C09-LB_C09 被引量:1
标识
DOI:10.1158/1535-7163.targ-23-lb_c09
摘要

Abstract KRAS, one of the most frequently mutated oncogenes in cancer, was considered undruggable until the development of covalent KRASG12C inhibitors. While these KRASG12C-targeted therapies exhibit clinical benefit, they do not address the most common KRAS mutant variants. QTX3034 is a potent, highly selective, orally bioavailable allosteric multi-KRAS inhibitor that is efficacious against a broad spectrum of the more common KRASG12D- and KRASG12V-mutated cancers in vitro and in vivo. In an effort to enhance anti-tumor activity of QTX3034 and to minimize the development of possible resistance mechanisms, we explored the potential synergy of combining QTX3034 with EGFR inhibitors in multiple KRAS-mutated tumor models. Cell viability assays over a 7-day period revealed that QTX3034 synergized with three different EGFR inhibitors (afatinib, cetuximab, erlotinib) to profoundly inhibit proliferation across multiple KRASG12D, KRASG12V, and KRASWT Amp mutant cell lines with strong ZIP synergy scores (>10). Combination of QTX3034 and afatinib exhibited a markedly greater inhibitory effect on KRAS-mutant colony formation compared to the respective single agents. Analysis of RAS downstream signaling revealed that the combination of QTX3034 and afatinib produced a more potent suppression of the MAPK pathway than either single agent alone in KRAS-mutant cells. Moreover, QTX3034 monotherapy induced a dose-dependent increase in EGFR phosphorylation in the KRASG12D-mutated cell line GP2D, while co-administration with afatinib robustly inhibited this EGFR activation. Combining QTX3034 and cetuximab elicited durable tumor regressions in KRASG12D-mutant cell line-derived xenograft models. Furthermore, tumor regressions in these combination studies were obtained using meaningfully lower doses of QTX3034 than needed to achieve tumor regression by monotherapy. Similar combinations improved QTX3034 anti-tumor activity in patient-derived xenograft models that exceeded monotherapy with either agent. Taken together, these data support the rationale to co-administer QTX3034 and EGFR inhibitors to optimize therapeutic benefit for patients with KRAS-mutated cancers. Citation Format: Yang J. Zhang, Jillian M. Silva, Yang W. Zhang, Elizabeth Donohue Vo, John M. Micozzi, Douglas Krauth, Arghyotri Sinha, Ben Reid, Brooke McDonough, Gregory M. Lee, Christopher C. Pan, Audrey Hospital, Juan I. Luengo, Cameron Pitt, Hong Lin. QTX3034, a potent and selective multi-KRAS inhibitor, synergizes with EGFR inhibitors and enhances anti-tumor activity [abstract]. In: Proceedings of the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics; 2023 Oct 11-15; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2023;22(12 Suppl):Abstract nr LB_C09.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
甜美的成败完成签到,获得积分10
刚刚
1秒前
CCC完成签到,获得积分10
3秒前
7秒前
Tomato发布了新的文献求助30
7秒前
7秒前
CodeCraft应助谦让的焱采纳,获得10
8秒前
HY兑完成签到,获得积分10
10秒前
852应助kkk采纳,获得10
11秒前
fengbeing完成签到,获得积分10
11秒前
12秒前
阿乐发布了新的文献求助10
12秒前
高高发布了新的文献求助10
13秒前
科科发布了新的文献求助50
17秒前
18秒前
18秒前
19秒前
由不尤完成签到 ,获得积分10
22秒前
谦让的焱发布了新的文献求助10
22秒前
CL完成签到,获得积分10
23秒前
筱er完成签到,获得积分10
23秒前
GDL发布了新的文献求助10
24秒前
Ammy发布了新的文献求助10
25秒前
李健应助upupup采纳,获得10
26秒前
32秒前
itsserene应助科研通管家采纳,获得20
32秒前
搜集达人应助科研通管家采纳,获得10
32秒前
NexusExplorer应助科研通管家采纳,获得10
32秒前
不配.应助科研通管家采纳,获得20
32秒前
33秒前
33秒前
懦弱的乐蕊完成签到 ,获得积分10
33秒前
33秒前
小梦发布了新的文献求助10
35秒前
李加一完成签到,获得积分10
36秒前
mm发布了新的文献求助10
37秒前
38秒前
取什么好呢应助LIN采纳,获得10
39秒前
安详靖柏完成签到,获得积分10
40秒前
42秒前
高分求助中
Sustainability in Tides Chemistry 2800
Kinetics of the Esterification Between 2-[(4-hydroxybutoxy)carbonyl] Benzoic Acid with 1,4-Butanediol: Tetrabutyl Orthotitanate as Catalyst 1000
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
Rechtsphilosophie 1000
Bayesian Models of Cognition:Reverse Engineering the Mind 888
Very-high-order BVD Schemes Using β-variable THINC Method 568
Chen Hansheng: China’s Last Romantic Revolutionary 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3138630
求助须知:如何正确求助?哪些是违规求助? 2789630
关于积分的说明 7791721
捐赠科研通 2445972
什么是DOI,文献DOI怎么找? 1300801
科研通“疑难数据库(出版商)”最低求助积分说明 626058
版权声明 601079